Skip to search formSkip to main contentSkip to account menu

sotagliflozin

Known as: Beta-l-Xylopyranoside, methyl 5-C-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-1-thio-, (5S)- 
An orally bioavailable inhibitor of the sodium-glucose co-transporter subtype 1 (SGLT1) and 2 (SGLT2), with potential antihyperglycemic activity… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
In 2016, the 21st Century Cures Act directed the Food and Drug Administration (FDA) to evaluate the potential use of real-world… 
2019
2019
Abstract Background: According to the centers for disease control and prevention, 14% of American adults have diabetes – 10% know… 
Review
2019
Review
2019
In den Vereinigten Staaten von Amerika sind 1,5Mio. Menschen von Diabetes mellitus Typ 1 betroffen, und die Zahl nimmt… 
Review
2018
Review
2018
ABSTRACT Introduction: Sotagliflozin is the first dual SGLT1/SGLT2 inhibitor developed for use in diabetes. Sotagliflozin blocks… 
2018
2018
Sodium glucose-cotransporter type 2 (SGLT-2) inhibitors constitute a novel class of antidiabetics, approved for the treatment of… 
Review
2018
Review
2018
Question In adults with type 1 diabetes, what are the efficacy and safety of adding sodiumglucose cotransporter 2 (SGLT-2… 
2017
2017
The sotagliflozin molecule exhibits two fundamentally different molecular conformations in form 1 {systematic name: (2S,3R,4R,5S… 
2014
2014
The investigational LX4211 may one day fill a need for these patients who are unable to eliminate a lot of glucose in urine and…